MannKind Corporation
MNKD · Nasdaq · USD · Market cap $1.3B · 591 employees
MannKind Corporation, a biopharmaceutical company, focuses on the provision of various solutions for transforming chronic disease care.
FAIL · Does not pass the screenPrice as of 20 Nov 2026Daily close, not a live quote
Screened 2026-11-20 · the tape above runs as of 12:17 UTC · two dates, stated on purpose · verdict and workings shown in full · never trimmed
Key facts today
- Price3.85 USD at the 20 Nov 2026 close
- Our value readUndervalued vs our fair value, as of 20 Nov 2026
- Our regime readMarkup, as of 15 Nov 2026
- Ethical screenDoes not pass
- OptionsOpen interest leans heavily to calls (put/call 0.11)
- Last reviewed20 Nov 2026 (1 day ago)
- Release timesRelease and earnings times on your chart: Event Guard Mentor
A summary of the dated readings below, not a live quote and not advice.
Our fair-value range: $4.50 to $6.59, base estimate $5.73 (screen dated 2026-11-20).
- Trend Markup
- Insiders insiders sold, $128,478, latest filing 2026-09-25
- Positioning no disclosures inside 60 days, left as found
- Options put/call open interest 0.11, read 2026-11-18
- Ethical does not pass the values gate
Our analytic regime reads on this name, dated and marked against the screened price. Small sample per name, and separate from the daily-framework accuracy on the Track Record page.
This name holds its markup label.
MannKind Corporation holds its Markup at $3.85. Consolidating, no directional conviction, held for 16 days.
| Phase | Markup |
| Quantitative state | Consolidating, no directional conviction, held for 16 days |
| Price at the screen | $3.85 |
| Valuation | N/A trailing · 25.08 forward price to earnings |
| Values screen | FAIL · score 70.0 |
| Beta | 1.09 |
Five Screens: MNKD's Results
FAIL. Debt ratio
| Test | Figure | Limit | Status |
|---|---|---|---|
| Business activity | Permissible | Permissible core business | Pass |
| Debt load | 46.38% | Below 33% | Fail |
| Interest-bearing cash | 0.63% | Below 33% | Pass |
| Receivables | 14.30% | Below 49% | Pass |
| Revenue purity | 2.31% | Below 5% | Pass |
Definitions, sources and threshold rules: ticker values-screen methodology.
The Ethical ReadWhy It Falls Short, in Plain English
MannKind's business is in a permissible area, but its interest-bearing debt is about 46% of the company, well over the ~33% line, so it does not pass on the financial screens.
Read as at 20 Nov 2026. It updates when the underlying figures move, and past reads are kept below. How we screen.
Follow this verdict
Get an email when MNKD's ethical verdict changes
Today MNKD does not pass the screen. If new figures move it to a pass, we send you one short email with the before and after. Verdicts change rarely, so you may not hear from us for a long time.
Free, no account needed. Every email has a link to stop.
The Fair Value Range
Our analysis reads Undervalued to fair value, as of 20 Nov 2026: it trades at roughly a 33% discount to our $5.73 fair value, 24.00% revenue growth.
USD, 2026-11-20 screen. A 32.8% under base.
Street: 9 covering, consensus Strong Buy. Average target +108%.
Biotech chasing diabetes relief still burns cash
Imagine a patient managing diabetes who needs reliable new treatments. MannKind develops options for that and other chronic conditions, yet it still reports a negative profit margin of 7 percent despite 15 percent revenue growth. With an unknown moat and an opportunity rating of none, the business does not clear our bar even though the ethical screen returns a pass.
The forward price to earnings sits at 20.9 times while eight analysts carry a strong buy consensus and a median target of 7 dollars against the current 4.03 dollar price. Our own fair value of 5.29 dollars implies some headroom, but the absence of a clear competitive edge leaves the story too thin to justify a position.
High execution risk remains the core issue in a field where late stage setbacks can erase years of progress. The numbers show promise on paper, yet without proven durability the setup stays speculative. Analysis, not advice.
| Forward P/E | 25.1xfairly priced for its growth rate |
| EPS, trailing | -0.24 |
| EPS, forward | 0.16 |
| Revenue growth | +24.0%strong top-line growth |
| Profit margin | -18.1%currently unprofitable |
| FCF yield | -0.47% |
| Current ratio | 2.22comfortably covers its short-term bills |
| Beta | 1.09moves a little more than the market |
| Short interest, float | 0.08% |
| 52-week range | 2.23 - 6.51 |
| Market cap | $1.3B |
| Employees | 591 |
MNKD-specific watchpoints · The things to watch: it's a small-cap, so the share price can swing harder than the market; as a biotechnology name, trial and regulatory outcomes can move it sharply either way.
Metric definitions and interpretation rules: ticker-page methodology.
Every Entry, As Written
The framework has shifted from distribution to markup since the last review.
Earnings landed in this window. Ethical screening: FAIL.
Written on its date, before the outcome; never pruned.
- MannKind to Participate in Upcoming Investor Conferences Yahoo Finance · 11d ago
- MannKind (MNKD) Q3 2026 Earnings Call Transcript Yahoo Finance · 15d ago
- MannKind Corporation Q3 2026 Earnings Call Summary Yahoo Finance · 15d ago
- MannKind Corp (MNKD) Q3 2026 Earnings Call Highlights: Revenue Jumps 24% as FuroSix ReadyFlow ... Yahoo Finance · 15d ago
- Is MannKind (MNKD) Trading At A Discount Following Its Mixed Third Quarter Results? Yahoo Finance · 15d ago
Headlines from third-party outlets, linked for reference: not our reporting, not advice.
Screened names in the same industry · explore each on its own page.
| Date | Insider | Title | Type | Shares | Value |
|---|---|---|---|---|---|
| 2026-09-25 | Binder Steven B. | Dir | S - Sale | 39,051 | $128,478 |
| 2026-09-10 | Binder Steven B. | Dir | S - Sale | 33,558 | $127,856 |
Public filings, recorded as found. The full tape lives at Insider Intelligence.
| Period | Price then | Price return | Divs per share | $1,000 became | Total return |
|---|---|---|---|---|---|
| 1 month | $3.36 | +7.0% | · | $1,070 | +7.0% |
| 2 months | $2.57 | +39.9% | · | $1,399 | +39.9% |
| 3 months | $2.82 | +27.5% | · | $1,275 | +27.5% |
| 6 months | $5.81 | -38.1% | · | $619 | -38.1% |
| 1 year | $3.92 | -8.3% | · | $917 | -8.3% |
| 2 years | $4.49 | -19.9% | · | $801 | -19.9% |
| 3 years | $4.03 | -10.8% | · | $892 | -10.8% |
| 5 years | $4.05 | -11.2% | · | $888 | -11.2% |
Historical returns from market close data. Past performance does not guarantee future results.
This entry now belongs to the ledger. Whatever MNKD does next, these words stay.
Thirteen thousand names carry this page. One desk keeps them honest.
Membership opens the full screen archive, the composites built from it, and the daily coverage that prices what the screen approves.
Join the deskScreening is research, not a fatwa and not financial advice. Figures are drawn from public accounts at the screen date shown. Always manage your risk.